SG/PUT/NOVO-NORDISK B/800/0.1/20.06.25 Stock

SG/PUT/NOVO-NORDISK B/800/0.1/20.06.25 Share Price

DE000SU9CVY6

Market Closed - Bid/Ask 19:23:00 03/07/2024 BST			After market 20:24:58
0.8 ^EUR	+12.68%		0.815	+1.87%

Current month	+9.86%
1 month	-17.89%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart NOVO NORDISK A/S

Chart SG/PUT/NOVO-NORDISK B/800/0.1/20.06.25

Latest news about NOVO NORDISK A/S

Sector Update: Health Care Stocks Fall in Afternoon Trading	05:52pm	MT
Ozempic, Wegovy Linked to Risk of Blinding Eye Condition, Study Shows	05:08pm	MT
Top Midday Stories: Southwest Board Approves Shareholder Rights Plan; National Amusements Agrees to Preliminary Deal to Sell Paramount to Skydance; Ozempic, Wegovy Linked to Blinding Eye Condition, Study Says	04:59pm	MT
Ozempic, Wegovy Linked to Risk of Blinding Eye Condition, Study Shows	04:51pm	MT

More news

Quotes 5-day view

Date	Price	Change
03/07/24	0.8	+12.68%
02/07/24	0.71	+7.58%
01/07/24	0.66	-7.04%
28/06/24	0.71	+1.43%
27/06/24	0.7	+1.45%

Real-time Boerse Frankfurt Warrants

Last update July 03, 2024 at 07:23 pm

More quotes

Static data

Product type	Warrants
Buy / Sell	PUT
Underlying	NOVO NORDISK A/S
Issuer	Société Générale
WKN	SU9CVY
ISIN	DE000SU9CVY6
Date issued	14/02/2024
Strike	800 kr
Maturity	20/06/2025 (352 Days)
Parity	10 : 1
Emission price	1.44 €
Emission volume	N/A
Settlement	Por diferencias
Currency	EUR

Technical Indicators

Highest since issue	1.65 €
Lowest since issue	0.63 €
Delta	0x
Omega	0.000000
Premium	0x
Gearing	15.9x
Moneyness	0.8269
Difference Strike	-167.5 kr
Difference Strike %	-20.94%
Spread	0.03 €
Spread %	3.61%
Intrinsic value	0.000000
Present value	0.8050

Company Profile

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (92.6%); - rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).

Sector

More about the company